Newsroom

Millions of people around the world continue to face barriers to prevention, diagnosis and treatment for chronic diseases such as heart disease and cancer. To help address these gaps, Novartis is scaling its community health programs from 11 to more than 30 countries by 2030, working alongside local partners to connect more people to care.

For more than three decades, Novartis has been committed to the fight against malaria, one of the world's deadliest diseases. Fortune has now recognized that work by naming our malaria program to its 2026 Change The World list.

Christian Diehl, Chief Data & Digital Officer, Novartis Biomedical Research

Novartis chemists receive “Heroes of Chemistry” honor from the American Chemical Society for work on CML drug discovery.

For a quarter of a century, Novartis and The Max Foundation have worked together to help people living with cancer in low- and middle-income countries access the care they need.

Novartis R&D is harnessing digital technologies to make smart decisions faster, aiming to reduce the time it takes to bring new options to patients

There is no shortage of conversation about what AI can do. Every day brings a new headline, a new capability, a new prediction about how work will change.

Novartis R&D leaders discuss how Novartis science, technology and strategy are shaping the next decade of innovation

The roots of Novartis reach back more than 250 years, to the chemical and scientific traditions that helped shape modern healthcare. Thirty years after its creation, a legacy of discovery and curiosity continues to guide its pursuit of new possibilities for patients.

Radioligand therapy (RLT) has helped change what’s possible in prostate cancer treatment, but Novartis continues to work on the next wave of innovations to bring new options to patients.

Novartis partners with the Special Olympics to support neuro‑inclusion and build environments where everyone belongs.

Polly Cooper, Clinical Development Function Head, UK